GoalVest Advisory’s Abiomed Inc ABMD Stock Holding History

GoalVest Advisory’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	–	–	564
2022 Q1	$0	Buy	+1	New	+$308	﹤0.01%	517

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GoalVest Advisory's ABMD Position: Q2 2022 in Review

GoalVest Advisory sold out of Abiomed Inc (ABMD) in Q2 2022, closing a stake of 1 share.

GoalVest Advisory first reported a position in ABMD in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 496 funds tracked by Wall St. Rank hold ABMD as of Q2 2022.

GoalVest Advisory reported no remaining Abiomed Inc position as of Q2 2022 after selling out during the quarter.
GoalVest Advisory sold 1 Abiomed Inc share in Q2 2022.
GoalVest Advisory first reported a position in Abiomed Inc in Q1 2022 and held it in 1 quarter.
GoalVest Advisory's Abiomed Inc position peaked at $0 in Q1 2022.
496 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2022.

Based on GoalVest Advisory's 13F filing for Q2 2022, filed 6 Jul 2022.